Members log in

Remember me

Do not refresh my screen on timeout

close

News

ABN shortlisted to host World Congress of Neurology 2021

Read More

Events

National Clinical Leaders’ away day 4th September

Read More

Trials and Surveys

 

Trials 

 

SANADII

SANADII needs you! With the end of recruitment in May 2017 please make every effort to recruit. Should you have any questions about recruitment (or trial in general) please contact Silviya Balabanova (trial coordinator) tel 0151 529 5464, or Tony Marson (CI). SANADII is a National Institute for Health Research's Health Technology Assessment programme (NIHR HTA) funded trial and it assesses the clinical and cost effectiveness of levetiracetam and zonisamide compared to standard treatments - lamotrigine and valproate over 5.5 years. For more information visit  www.sanad2.org.uk.

 

 

ECST-2

The Second European Carotid Surgery Trial (ECST-2) is a multicentre randomised controlled trial (RCT), funded by the NIHR Research for Patient Benefit Scheme and by the Stroke Association, UK.  The trial is designed to investigate the hypothesis that in patients with atherosclerotic carotid artery stenos is at low and intermediate risk for stroke, optimised medical treatment (OMT) will avoid the need for carotid revascularisation.  Asymptomatic or symptomatic patients with >50% carotid artery stenosis and a low to intermediate risk of recurrent stroke, will be randomly allocated to be treated by carotid revascularisation with OMT  (“immediate revascularisation”) or OMT alone (“delay revascularisation until more clearly indicated”).  Substudies of the trial include carotid plaque imaging with MRI and US, histological analysis of the plaque and genetics.  The ECST-2 Trial Group, led by Professor Martin Brown (Chief Investigator) is based at the UCL Institute of Neurology, London UK.  For further information on the trial please contact Dr Roland Featherstone, Trial Manager.  Alternatively you can visit the trial website.

 

 

Leber’s Hereditary Optic Neuropathy Gene Therapy Trial

We have started recruitment into these two LHON gene therapy trials for patients with the 11778 mtDNA mutation.    Rescue:  Vision loss for 6 months or less https://clinicaltrials.gov/ct2/show/NCT02652767?term=GenSight+Biologics&rank=2    Reverse:  Vision loss for 6-12 months https://clinicaltrials.gov/ct2/show/NCT02652780?term=GenSight+Biologics&rank=1    The procedure consists of an intravitreal injection of the viral vector (GS010) in one eye under topical anaesthesia.    Since this information was last circulated on the UK EGG mailing list, we have now received ethical approval to reduce the age threshold from 18 to 15 years old.    All travel expenses for the patient and an accompanying person (if required) will be covered.  If you have any eligible patients or any queries, please get in touch with me (Patrick.Yu-Wai-Man@ncl.ac.uk).

 


 

Surveys

Multiple Sclerosis Society funded research

Dear colleague and member of the ABN,

I hope that  you will be able to help us with a UK-wide online research project we are undertaking, as an independent academic study funded by a grant from the MS Society, and conducted by researchers at the University of Manchester.   This is a national survey of prescribers of disease modifying treatments (DMTs), across the UK, investigating differences in DMT prescribing practices and self-reported prescribing rates, and across different types of prescribers and service settings.   Taking part requires completing an anonymous online questionnaire, which comprises 50 short multiple-choice questions and will take around 15 minutes. Prescribers who complete the questionnaire will have the option to print their responses at the end of the survey.   Please note that responses are completely anonymous, data will be held securely at the University of Manchester, and results will be reported only at the group level so that no individuals can be identified by their responses.   Further information about taking part is provided on the survey welcome page.  

Link to the online survey: https://apps.mhs.manchester.ac.uk/surveys//TakeSurvey.aspx?SurveyID=DMTprescribers  

Please feel free to share this invitation and survey link with your colleagues and local networks, as we would like as many UK prescribers as possible to complete the questionnaire. Responses by the end of July would be very much appreciated.   *[Apologies for any duplication: You may receive the invitation to this online research more than once as the survey link is shared across professional networks. Please complete the survey only once.]*    

Regards and thank you in advance,  

Dr Elaine Cameron (University of Manchester) & Dr David Rog (Salford Royal NHS Foundation Trust)

 

Prognosis in MS

Dear ABN member
 
Researchers at the University of Southampton are looking for neurologists to take part in a MS research project.
 
The project is exploring your experiences of communicating prognosis to patients with Multiple Sclerosis. Participation will involve a telephone interview at a time and place that is convenient for you and the interview is predicted to last around 45 minutes to an hour.
 
In return for your participation, you will receive a £15 Amazon voucher and a certificate stating that you have helped with this research, which might be useful in your professional appraisal or revalidation. We would also be happy to provide a transcript of the conversation if you wish, for use as an example of reflection on one’s practice. The interview will provide an opportunity for reflection that may be useful for your appraisal. Ultimately, the research aims to contribute towards understanding and improving prognosis communication and Healthcare Professional-Patient relationships.
 
If you are interested in participating or simply want to find out more, please contact Samantha Hornsey at the University of Southampton (sh7g13@soton.ac.uk)

 

  

News

ABN shortlisted to host World Congress of Neurology 2021

Read More

Events

National Clinical Leaders’ away day 4th September

Read More